GlassScriptPhysician profile
Joseph Tran
NPI 1649916354
$891.09
in general payments reported to CMS, 2019-2025
19 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $301 · 2024: $433 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116.24 | 2023-2025 | Evenity, Prolia |
| Abbvie INC. | $97.80 | 2023-2025 | |
| Mylan Specialty L.P. | $97.39 | 2023-2024 | Yupelri |
| Dexcom, INC. | $95.79 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $77.65 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $67.04 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $58.04 | 2023 | Rexulti |
| Cochlear Americas | $55.86 | 2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Lilly USA, LLC | $34.98 | 2023-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $29.95 | 2023-2025 | Breztri, Farxiga |
| Insulet Corporation | $27.76 | 2024 | Omnipod |
| Grifols USA, LLC | $22.34 | 2024 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $20.89 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $16.59 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2023 | Jardiance, Tradjenta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.77 | 2023 | |
| Novo Nordisk INC | $14.53 | 2023 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $14.04 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $13.22 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.